HUP0300566A2 - Galantamin alkalmazása az Alzheimer-kórral összefüggő neuropszichiátriai viselkedésformák terápiájában - Google Patents
Galantamin alkalmazása az Alzheimer-kórral összefüggő neuropszichiátriai viselkedésformák terápiájábanInfo
- Publication number
- HUP0300566A2 HUP0300566A2 HU0300566A HUP0300566A HUP0300566A2 HU P0300566 A2 HUP0300566 A2 HU P0300566A2 HU 0300566 A HU0300566 A HU 0300566A HU P0300566 A HUP0300566 A HU P0300566A HU P0300566 A2 HUP0300566 A2 HU P0300566A2
- Authority
- HU
- Hungary
- Prior art keywords
- alzheimer
- disease
- galantamine
- neuropsychiatric
- treatment
- Prior art date
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title abstract 6
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 4
- 229960003980 galantamine Drugs 0.000 title abstract 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title abstract 3
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A galantamint számos krónikus betegség gyógyításában alkalmazzák. Agalantamin hatásosan és biztonsággal alkalmazható az Alzheimer-kórterápiájában is. Az Alzheimer-kór általában együtt járneuropszichiátriai rendellenességekkel. Jelen találmánybanbebizonyítják, hogy a galantamin hatékonyan alkalmazható az Alzheimer-kóros betegeknél a neuropszichiátriai viselkedésformák előfordulásigyakoriságának csökkentésében vagy a neuropszichiátriai státuszstabilizálásában. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19425900P | 2000-04-03 | 2000-04-03 | |
PCT/EP2001/003553 WO2001074339A2 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0300566A2 true HUP0300566A2 (hu) | 2003-06-28 |
HUP0300566A3 HUP0300566A3 (en) | 2004-10-28 |
Family
ID=22716898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300566A HUP0300566A3 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1272192A2 (hu) |
JP (1) | JP2003528913A (hu) |
KR (1) | KR20020086911A (hu) |
CN (1) | CN1430514A (hu) |
AU (2) | AU2001265844B2 (hu) |
BG (1) | BG107093A (hu) |
BR (1) | BR0109770A (hu) |
CA (1) | CA2310926C (hu) |
CZ (1) | CZ20023543A3 (hu) |
EE (1) | EE200200554A (hu) |
HR (1) | HRP20020778A2 (hu) |
HU (1) | HUP0300566A3 (hu) |
IL (1) | IL152061A0 (hu) |
MX (1) | MXPA02009777A (hu) |
NO (1) | NO20024746L (hu) |
PL (1) | PL361272A1 (hu) |
RU (1) | RU2002129298A (hu) |
SK (1) | SK15422002A3 (hu) |
WO (1) | WO2001074339A2 (hu) |
ZA (1) | ZA200207935B (hu) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
EP1651234B1 (en) | 2003-07-25 | 2007-09-26 | F. Hoffmann-La Roche Ag | Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders |
DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
ES2634421T3 (es) | 2008-03-27 | 2017-09-27 | Chase Pharmaceuticals Corporation | Uso y composición para tratar la demencia |
WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
CA2986431C (en) * | 2015-05-18 | 2020-04-14 | Synaptec Development Llc | Galantamine clearance of amyloid.beta. |
CN117957003A (zh) * | 2021-09-09 | 2024-04-30 | 上海日馨医药科技股份有限公司 | 治疗神经退行性疾病的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
WO2000030446A1 (en) | 1998-11-23 | 2000-06-02 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
CA2358062C (en) * | 1998-12-24 | 2006-12-19 | Janssen Pharmaceutica N.V. | Controlled release galantamine composition |
CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
-
2001
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Application Discontinuation
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 EP EP01943200A patent/EP1272192A2/en not_active Withdrawn
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Application Discontinuation
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL152061A0 (en) | 2003-05-29 |
AU2001265844B2 (en) | 2005-04-14 |
CN1430514A (zh) | 2003-07-16 |
CA2310926A1 (en) | 2000-10-04 |
WO2001074339A2 (en) | 2001-10-11 |
EP1272192A2 (en) | 2003-01-08 |
WO2001074339A3 (en) | 2002-09-12 |
KR20020086911A (ko) | 2002-11-20 |
AU6584401A (en) | 2001-10-15 |
HUP0300566A3 (en) | 2004-10-28 |
RU2002129298A (ru) | 2004-03-27 |
CA2310926C (en) | 2002-10-15 |
JP2003528913A (ja) | 2003-09-30 |
PL361272A1 (en) | 2004-10-04 |
CZ20023543A3 (cs) | 2003-03-12 |
SK15422002A3 (sk) | 2003-04-01 |
ZA200207935B (en) | 2004-01-30 |
BG107093A (bg) | 2003-06-30 |
BR0109770A (pt) | 2003-02-04 |
NO20024746D0 (no) | 2002-10-02 |
NO20024746L (no) | 2002-11-28 |
MXPA02009777A (es) | 2003-03-27 |
HRP20020778A2 (en) | 2004-04-30 |
EE200200554A (et) | 2004-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200509968A (en) | Prevention and treatment of synucleinopathic disease | |
GB0108592D0 (en) | Therapeutic agents | |
HK1087398A1 (en) | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | |
YU37602A (sh) | Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns | |
HUP0300426A2 (hu) | Antihipertenzív és anti-angiogén szerek terápiás kombinációja és ezeket tartalmazó gyógyszerkészítmények | |
GB0223040D0 (en) | Therapeutic compounds | |
HRP20020593B1 (en) | Brain, spinal and nerve injury treatment | |
WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
EP1390491A4 (en) | METHOD OF TREATING NEURODEGENERATIVE, PSYCHIATRIC AND OTHER DISEASES WITH DEACETYLASE INHIBITORS | |
MX2007001679A (es) | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. | |
BG105575A (en) | Method and agent for the treatment of cerebral ischaemia | |
DK1296671T3 (da) | Gabapentinanaloger til sövnforstyrrelser | |
DE69830512D1 (de) | Heilmittel für neurodegenerative krankheiten | |
DK0668763T3 (da) | Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme | |
CY1106155T1 (el) | Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους | |
MY135838A (en) | Methods for the treatment of mental disorders | |
MXPA05009986A (es) | Tratamiento de la enfermedad de alzheimer. | |
DE602004023762D1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren | |
HUP0300566A2 (hu) | Galantamin alkalmazása az Alzheimer-kórral összefüggő neuropszichiátriai viselkedésformák terápiájában | |
MXPA03011702A (es) | Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias. | |
GB0020504D0 (en) | Therapeutic method | |
HUP0204048A2 (hu) | Dezloratadin alkalmazása allergiás és gyulladásos tünetek kezelésére | |
DE69928521D1 (de) | Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit | |
DE60138385D1 (de) | Heilmittel zur behandlung von erkrankungen des sehnervs | |
IL147188A (en) | Use of il6ril6 chimera in the manufacture of a remedy for neurological diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |